rasagiline has been researched along with davunetide in 1 studies
| Studies (rasagiline) | Trials (rasagiline) | Recent Studies (post-2010) (rasagiline) | Studies (davunetide) | Trials (davunetide) | Recent Studies (post-2010) (davunetide) |
|---|---|---|---|---|---|
| 535 | 72 | 314 | 129 | 5 | 62 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amit, T; Bar-Am, O; Fridkin, M; Mandel, SA; Youdim, MB; Zheng, H | 1 |
1 review(s) available for rasagiline and davunetide
| Article | Year |
|---|---|
From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Cycle Checkpoints; Chelating Agents; Cholinesterase Inhibitors; Humans; Hydroxyquinolines; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oligopeptides; Piperazines | 2012 |